Duration of androgen suppression in prostate cancer.
Badiozamani
Kas R
KR
D000726:Androgen Antagonists / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen